Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy
BACKGROUND: According to the renal phospholipase A2 receptor (PLA2R) immunohistochemistry, idiopathic membranous nephropathy (iMN) could be categorized into PLA2R-associated and non-PLA2R-associated iMN. This study aimed to examine whether the non-PLA2R-associated iMN had any difference in clinical features compared with PLA2R-associated iMN.
METHODS: A total of 231 adult patients diagnosed as iMN were recruited to this retrospective study. Renal PLA2R expression was examined by immunofluorescence. Among these patients, 186 (80.5%) with complete baseline clinical data were used for further study. Urinary protein excretion, serum albumin, and creatinine were analyzed. For those patients with follow-up longer than 1 year, the relationship between PLA2R and response to immunosuppressants were analyzed. The t-test was used for parametric analysis and the Mann-Whitney U-test was used for nonparametric analysis. Categorical variables were described as frequencies or percentages, and the data were analyzed with Pearson's Chi-square test or Fisher's exact test.
RESULTS: Of the 231 iMN patients, 189 showed renal detectable PLA2R expression (81.8%). The baseline serum creatinine, serum albumin, and urine protein excretion were not significantly different between PLA2R-associated (n = 145) and non-PLA2R-associated iMN patients (n = 41). However, about 1/3 of the non-PLA2R-associated iMN had abnormal serological tests, significantly more common than PLA2R-associated iMN (31.7% vs. 8.3%, P = 0.000). The non-PLA2R-associated iMN had lower C4 levels compared with PLA2R-associated iMN (P = 0.004). The non-PLA2R-associated iMN patients also showed a better response to immunosuppressants (complete remission [CR] 42.9%; partial remission [PR] 14.3%) compared with PLA2R-associated iMN (CR 3.2%; PR 48.4%, P = 0.004) at the 3rd month.
CONCLUSIONS: There were no significant differences in serum creatinine, albumin, and urine protein excretion between PLA2R-associated and non-PLA2R-associated iMN, while the non-PLA2R-associated iMN patients showed more abnormal serological tests. The non-PLA2R-associated iMN seemed to respond more quickly to the immunosuppressive therapy compared with PLA2R-associated iMN.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
---|---|
Enthalten in: |
Chinese medical journal - 130(2017), 8 vom: 20. Apr., Seite 892-898 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xu, Ning-Xin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Autoantibodies |
---|
Anmerkungen: |
Date Completed 17.08.2017 Date Revised 11.03.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.4103/0366-6999.204096 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM270852484 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM270852484 | ||
003 | DE-627 | ||
005 | 20231224231439.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4103/0366-6999.204096 |2 doi | |
028 | 5 | 2 | |a pubmed24n0902.xml |
035 | |a (DE-627)NLM270852484 | ||
035 | |a (NLM)28397717 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Xu, Ning-Xin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.08.2017 | ||
500 | |a Date Revised 11.03.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: According to the renal phospholipase A2 receptor (PLA2R) immunohistochemistry, idiopathic membranous nephropathy (iMN) could be categorized into PLA2R-associated and non-PLA2R-associated iMN. This study aimed to examine whether the non-PLA2R-associated iMN had any difference in clinical features compared with PLA2R-associated iMN | ||
520 | |a METHODS: A total of 231 adult patients diagnosed as iMN were recruited to this retrospective study. Renal PLA2R expression was examined by immunofluorescence. Among these patients, 186 (80.5%) with complete baseline clinical data were used for further study. Urinary protein excretion, serum albumin, and creatinine were analyzed. For those patients with follow-up longer than 1 year, the relationship between PLA2R and response to immunosuppressants were analyzed. The t-test was used for parametric analysis and the Mann-Whitney U-test was used for nonparametric analysis. Categorical variables were described as frequencies or percentages, and the data were analyzed with Pearson's Chi-square test or Fisher's exact test | ||
520 | |a RESULTS: Of the 231 iMN patients, 189 showed renal detectable PLA2R expression (81.8%). The baseline serum creatinine, serum albumin, and urine protein excretion were not significantly different between PLA2R-associated (n = 145) and non-PLA2R-associated iMN patients (n = 41). However, about 1/3 of the non-PLA2R-associated iMN had abnormal serological tests, significantly more common than PLA2R-associated iMN (31.7% vs. 8.3%, P = 0.000). The non-PLA2R-associated iMN had lower C4 levels compared with PLA2R-associated iMN (P = 0.004). The non-PLA2R-associated iMN patients also showed a better response to immunosuppressants (complete remission [CR] 42.9%; partial remission [PR] 14.3%) compared with PLA2R-associated iMN (CR 3.2%; PR 48.4%, P = 0.004) at the 3rd month | ||
520 | |a CONCLUSIONS: There were no significant differences in serum creatinine, albumin, and urine protein excretion between PLA2R-associated and non-PLA2R-associated iMN, while the non-PLA2R-associated iMN patients showed more abnormal serological tests. The non-PLA2R-associated iMN seemed to respond more quickly to the immunosuppressive therapy compared with PLA2R-associated iMN | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Autoantibodies |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Receptors, Phospholipase A2 |2 NLM | |
700 | 1 | |a Xie, Qiong-Hong |e verfasserin |4 aut | |
700 | 1 | |a Sun, Zhu-Xing |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jia |e verfasserin |4 aut | |
700 | 1 | |a Li, Yan |e verfasserin |4 aut | |
700 | 1 | |a Wang, Liang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Shao-Jun |e verfasserin |4 aut | |
700 | 1 | |a Xue, Jun |e verfasserin |4 aut | |
700 | 1 | |a Hao, Chuan-Ming |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Chinese medical journal |d 1979 |g 130(2017), 8 vom: 20. Apr., Seite 892-898 |w (DE-627)NLM000002755 |x 2542-5641 |7 nnns |
773 | 1 | 8 | |g volume:130 |g year:2017 |g number:8 |g day:20 |g month:04 |g pages:892-898 |
856 | 4 | 0 | |u http://dx.doi.org/10.4103/0366-6999.204096 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 130 |j 2017 |e 8 |b 20 |c 04 |h 892-898 |